Creative Diagnostics' research team studies multiple influenza A strains, including H9N2, H1N1, and H3N2. The company offers clients a portfolio of customized and standardized preclinical services utilizing mouse infection models to evaluate pathogenic mechanisms, humoral immune responses, and protective efficacy induced by wild-type influenza A viruses or influenza vaccines. The mouse models include H9N2 Avian Influenza Mouse Model, H1N1 Strain Mouse Model, Pdm H1N1 Strain Mouse Model, and H3N2 Strain Mouse Model.

As a scientists-founded and scientists-driven leading biotechnological company, Creative Biogene focuses on developing high quality products and services, as well as proprietary technology to support the research in the field of basic life sciences research, biomedical development, industrial synthetic application and preclinical drug discovery.

Ace Therapeutics is a preclinical contract research provider dedicated to offering comprehensive one-stop services. Our expertise spans across various preclinical services, including efficacy testing, pharmacokinetics, toxicology, and biomarker development, to support clients in their research and development efforts. With a team of experienced researchers and state-of-the-art facilities, we aim to support the development of innovative therapies. From early-stage research to preclinical studies, we provide tailored solutions that help advance drug development processes. Our expertise, cutting-edge technology, and commitment to quality ensure that we deliver reliable and efficient preclinical services to meet the needs of our clients.

Creative Bioarray is an innovative biotechnology company whose mission focuses on developing unique technologies that provide global scientists with high quality products and satisfactory services to facilitate the investigation of life science researches.

Creative Diagnostics' SpeX® Earthworm Microsome model is a crucial for studying drug metabolism and the environmental fate of pharmaceuticals within soil biocommunity systems. This model assists researchers in evaluating the environmental risks and ecotoxicity of pharmaceuticals. Additionally, the metabolic mechanisms of earthworms and mammalian intestines are highly similar (both are rich in CYP450 enzymes and transferases), making this novel product an ideal complementary model for mammalian drug metabolism research. It effectively simulates the first-pass metabolism of orally administered drugs and provides a vital tool for bioavailability studies. Most significantly, as a unique non-mammalian model, earthworm microsomes open new avenues for exploring novel metabolic pathways and drive innovation in drug metabolism research.

Leading US peptide CDMO and research supplier, formerly known as American Peptide Company and New England Peptide. Provides GMP peptide manufacturing, catalog peptides, and custom synthesis services.

US-based CDMO and contract laboratory with 45+ years of experience providing analytical testing, stability studies, and impurity analysis for peptides, biologics, and oligonucleotides across all development stages.

One of the world's largest peptide CDMOs. FDA-inspected cGMP facility with 500+ chemists supporting pharmaceutical and biotech companies from development through commercial production. Five FDA inspections passed.

FDA-registered pharmaceutical testing lab and contract research organization. Provides GMP analytical testing for peptide APIs and drug products including identity, purity, potency, and impurity profiling.

Independent FDA-registered pharmaceutical testing laboratory providing release and stability testing for compounded peptide preparations. Services include sterility, potency, purity, and endotoxin testing.